ArticleAdvanced healthcare materials2026
ROS-Triggered Microgels for Programmable Drug Release in Volumetric Muscle Loss Repair.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hydrogels for Skeletal Muscle Regeneration: Design, Fabrication, and Future Applications.ACS polymers Au · 2026Review
- ROS-Triggered Microgels for Programmable Drug Release in Volumetric Muscle Loss Repair.Advanced healthcare materials · 2026Article
- Innovations in skeletal muscle regeneration: from physiology to bioengineering approaches for repair and restoration.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Volumetric muscle loss (VML), frequently resulting from traumatic or surgical damage, causes significant muscle mass depletion and fibrosis, and presents major challenges to effective regeneration. In this study, reduced graphene-containing hyaluronic acid microgels (rGHMs) are developed as a multifunctional platform for reactive oxygen species (ROS)-scavenging and ROS-responsive drug delivery to treat VML. The rGHMs are synthesized via a water-in-oil emulsion and subsequent chemical reduction. rGHMs demonstrate superior antioxidative capability, curcumin loading efficiency, and ROS-mediated drug release properties compared to HA microgels (HMs) and unreduced graphene-oxide containing HA microgels (GHMs). In particular, curcumin-loaded rGHMs (Cur/rGHMs) significantly facilitate curcumin release with a 2.6-fold increase under 1 mm H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.